Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Veracyte is a genomic diagnostics company specializing in molecular tests that help physicians make treatment decisions across thyroid, lung, and other cancers. The company's flagship products include Afirma for thyroid nodules, Percepta for lung nodules, and Prosigna for breast cancer, with revenue driven by test volume growth and Medicare/commercial reimbursement rates. Operating at scale with 67% gross margins and recently achieving profitability, the stock trades on test adoption rates, reimbursement stability, and pipeline expansion into new cancer indications.
Veracyte generates revenue per test performed, typically reimbursed by Medicare ($3,200-$4,500 per Afirma test) and commercial payers at negotiated rates. The company operates CLIA-certified laboratories processing physician-ordered biopsies and tissue samples, with pricing power derived from clinical validation studies demonstrating reduced unnecessary surgeries and improved patient outcomes. Competitive advantages include proprietary genomic classifiers with published clinical utility data, established relationships with endocrinologists and pulmonologists, and Medicare coverage determinations that create reimbursement moats. The business model benefits from recurring revenue as physicians adopt tests into standard clinical pathways.
Quarterly test volume growth rates across Afirma, Percepta, and Envisia platforms - acceleration or deceleration versus 20-25% historical growth
Medicare reimbursement decisions and rate changes - any coverage expansions, restrictions, or pricing adjustments for key tests
New product launches and clinical validation study results - pipeline expansion into prostate, bladder, or other cancer indications
Commercial payer contract wins and reimbursement rate negotiations - coverage policies from major insurers affecting revenue per test
Gross margin trajectory - improvements signal operating leverage and path to sustained profitability
Medicare reimbursement policy changes - CMS coverage decisions or rate cuts could materially impact revenue per test and profitability, particularly for Afirma which depends on favorable Medicare rates
Clinical guideline evolution - Changes to thyroid or lung nodule management guidelines by medical societies could reduce test utilization if alternative diagnostic pathways gain favor
Technological disruption from liquid biopsy or AI-based imaging diagnostics that could provide non-invasive alternatives to tissue-based genomic testing
Competition from larger diagnostics companies (Quest, LabCorp, Exact Sciences) with greater scale, sales force reach, and ability to bundle tests into broader oncology portfolios
Academic medical centers developing in-house genomic testing capabilities, bypassing commercial reference laboratories
Payer pressure to consolidate diagnostic testing with lower-cost providers or demand outcomes-based pricing models
Cash burn risk if test volume growth decelerates - While recently profitable, the company has limited margin cushion and could return to losses if growth disappoints
Equity dilution risk - With $2.9B market cap and history of equity financing, future capital raises for acquisitions or pipeline development could dilute shareholders
low - Cancer diagnostics are medically necessary procedures with limited discretionary component, making volumes relatively recession-resistant. However, elective procedure volumes can decline modestly during severe economic downturns if patients delay non-urgent biopsies due to insurance concerns or cost sensitivity. The company's Medicare-heavy payer mix (estimated 40-50% of revenue) provides stability, though commercial insurance coverage can tighten during economic stress.
Rising interest rates create modest headwinds through higher discount rates applied to future cash flows, compressing valuation multiples for unprofitable or low-margin growth companies. With minimal debt (0.03 D/E), financing costs are negligible, but the company's growth stock profile makes it sensitive to rate-driven multiple compression. Higher rates also increase opportunity cost for investors, reducing appetite for companies trading at 5.8x sales with modest near-term profitability.
Minimal - The company has negligible debt and strong liquidity (6.23 current ratio), eliminating refinancing risk. Revenue depends on healthcare payer reimbursement rather than consumer credit, though commercial insurance coverage can be affected by employer cost pressures during credit contractions. Bad debt risk is low given Medicare and established commercial payer contracts.
growth - Investors are attracted to 23.5% revenue growth, expanding test adoption in large addressable markets (thyroid, lung cancer diagnostics), and recent profitability inflection. The stock appeals to healthcare growth investors focused on precision medicine and genomic diagnostics themes, willing to pay premium valuations (5.8x sales) for sustainable double-digit volume growth and margin expansion potential. Recent 132% net income growth signals operating leverage inflection that attracts momentum investors.
high - Small-cap healthcare stock ($2.9B market cap) with significant price sensitivity to quarterly results, reimbursement news, and clinical study outcomes. The -9.7% one-year return with 20.8% six-month gain demonstrates volatility typical of growth-stage diagnostics companies. Limited analyst coverage and institutional ownership concentration can amplify price swings on earnings surprises or Medicare policy announcements.
